Pretreatment prognostic factors of local recurrence-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 3, 2008, Pages 213-218

  Jeremić, Branislav ^a,b   Miličić, Biljana ^a  

^a University Hospital   (Serbia)

^b Applied Radiobiology and Radiotherapy Section   (Austria)

Author keywords

Chemotherapy; Head and neck cancer; Prognostic factors; Radiation therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; NASOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; PRIMARY TUMOR; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; ADJUVANT CHEMOTHERAPY; AGED; CANCER STAGING; DISEASE FREE SURVIVAL; FOLLOW UP; HEAD AND NECK TUMOR; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY;

AGED; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLATINUM; PROGNOSIS; RADIATION DOSAGE;

EID: 44949125691     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318161dbef     Document Type: Article

References (36)

1. Tupchong L, Scott CB, Blitzer PH, et al. Randomized study of preop-erative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys. 1991;20:21-28.
2. Bartelink H, Breur K, Hart G, et al. The value of postoperative radiotherapy as an adjuvant to radical neck dissection. Cancer. 1983;52: 1008-1013.
3. Huang D, Johnson CR, Schmidt-Ullrich RK, et al. Incompletely resected advanced squamous cell carcinoma of the head and neck: the effectiveness of adjuvant vs. salvage radiotherapy. Radiother Oncol. 1992;24: 87-93.
4. Nisi KW, Foote RL, Bonner JA, et al. Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: improved local-regional disease control compared with surgery alone. Int J Radiat Oncol Biol Phys. 1998;41:371-377.
5. Bernier J, Domenge C, Ozsahin M, et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952.
6. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
7. Cox JD, Pajak TF, Marcial VA, et al. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of Radiation Therapy Oncology Group, protocol 83-13. Int J Radiat Oncol Biol Phys. 1990; 18:515-521.
8. Ang KK, Peters LJ, Weber RS, et al. Concomitant boost radiotherapy schedule in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys. 1990;19:1339-1345.
9. Horiot J-C, Bontemps P, van der Bogaert W, et al. Accelerated fraction-ation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol. 1997; 44:111-121.
10. Dische S, Saunders M, Barrett A, et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck. Radiother Oncol. 1997;44:123-136.
11. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7-16.
12. Bourhis J, Overgaard J, Audry H, et al. Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843-854.
13. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. New Engl J Med. 1998;338:1798-1804.
14. Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol. 1997;43:29-37.
15. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;18:1458-1464.
16. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radioche-motherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16:1318-1324.
17. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91: 2081-2086.
18. Adelstein DJ, Sexton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck. 1997;19:567-575.
19. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol. 2005;23: 1125-1135.
20. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949- 955.
21. Bourhis J, Amand C, Pignon J-P, on behalf of the MACH-NC Collaborative Group. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradio-therapy. J Clin Oncol. 2004;22(Suppl 14):5505.
22. Glatstein E, Makuch RW. Illusion and reality: practical pitfalls in interpreting clinical trials. J Clin Oncol. 1984;2:488-497.
23. Simon R. Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep. 1984;68:185-192.
24. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710.
25. Chiesa F, Tradati N, Mauri S, et al. Prognostic factors in head and neck oncology. A critical appraisal for use in clinical practice. Anticancer Res. 1998;18:4769-4776.
26. Jeremic B, Milicic B, Dagovic A, et al. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2004;22:3540-3548.
27. Cerezo L, Millan I, Torre A, et al. Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. A multivariate analysis of 492 cases. Cancer. 2000;69:1224- 1234.
28. Johansen LV, Grau C, Overgaard J. Hypopharyngeal squamous cell carcinoma. Treatment results in 138 consecutively admitted patients. Acta Oncol. 2000;39:529-536.
29. Johansen LV, Grau C, Overgaard J. Squamous cell carcinoma of the nasopharynx. An analysis of treatment results in 149 consecutively admitted patients. Acta Oncol. 2001;40:801-809.
30. Lee RW, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 1998;42:1069-1075.
31. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
32. Prosnitz RG, Yao B, Farrell CL, et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2005;61:1087-1095.
33. Rudat V, Dietz A, Schramm O, et al. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemo-therapy. Radiother Oncol. 1999;53:119-125.
34. Grabenbauer GG, Steininger H, Meyer M, et al. Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol. 1998;47:175-183.
35. Cooper JS, Farnan NC, Asbell SO, et al. Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. Cancer. 1996;77:1905-1911.
36. Johansen LV, Grau C, Overgaard J. Squamous cell carcinoma of the oropharynx. An analysis of treatment results in 289 consecutively admitted patients. Acta Oncol. 2000;39:985-994.